A prediction market platform has notified the CFTC it will terminate its Volume Incentive Program by October 13, without stating a reason. The platform set a new record with $52.98 billion in trading volume for September, surpassing previous months. The CFTC is investigating over $5 billion in Ether perpetual futures transactions due to unusual trading patterns, though the platform denies manipulative trading, attributing activity to market makers and high-frequency traders. Meanwhile, the company is seeking $1 billion in funding, potentially valuing it at $40 billion, and expanding its cryptocurrency futures offerings.
Kalshi's termination of its trader incentive program is presented here with Pluang's market data for context. For readers following cryptocurrency markets, 40 of 50 major cryptocurrencies on Pluang rose today, while 9 fell. Notable movers include DOT at Rp22.284 with a 4.09% increase, COTI at Rp240 up 3.38%, and VET at Rp163 rising 3.29%, as of Oct 01, 2026 13:31 WIB.
Quant (QNT) token price increased to $300, up 5.16% over 24 hours, with a notable 4.09% rise within one hour on October 1. This price movement was recorded on Binance's spot QNT/USDT market. During the same hour, liquidations of short positions reach...
Pantheon Resources PLC has named David Wilkins as its new CEO, effective immediately. Wilkins, an industry veteran with over 40 years of experience in Alaska's energy sector, joined the board in March and replaces Max Easley, who is moving to a senio...
Primary Health Properties PLC has finalized financial terms and due diligence for its joint venture deals, aiming to use asset sale proceeds to reduce debt. The company targets lowering its net debt to EBITDA ratio below 9.5 and loan-to-value ratio u...
Rothe Development has filed for an IPO to raise working capital, partly to repay the CEO's personally guaranteed acquisition note. Despite a $635 million government contract backlog through 2025, the company shows uneven revenue growth, very low prof...
Defence Therapeutics announced its participation in the 17th World ADC San Diego conference, where CEO Dr. Amie Phinney will discuss advancements in intracellular delivery for antibody-drug conjugates (ADCs). The company will showcase its proprietary...
